Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cannara BiotechLOVFF 83 Debt-to-EBITDA is 1.03 as of May. 2026, which is 51% below its 10-year median of 2.12. GuruFocus rates LOVFF with a GF Score™ of 83/100 and a GF Value™ of $1.22 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 690 Drug Manufacturers companies, Cannara Biotech ranks better than 53.33% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Cannara Biotech's Debt-to-EBITDA or its related term are showing as below:
LOVFF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.75 Med: 2.12 Max: 6.51
Current: 1.46
During the past 8 years, the highest Debt-to-EBITDA Ratio of Cannara Biotech was 6.51. The lowest was -7.75. And the median was 2.12.
LOVFF's Debt-to-EBITDA is ranked better than 53.33% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.65
vs LOVFF: 1.46
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Cannara Biotech Debt-to-EBITDA Related Terms
Cannara Biotech Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (May. 2026) EBITDA data.
Cannara Biotech (LOVFF) has a Debt-to-EBITDA of 1.03 as of May. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cannara Biotech. This is 51% below median its historical median of 2.12. According to the industry distribution chart, Cannara Biotech ranks #322 out of 690 companies in the Drug Manufacturers industry, placing it in the top 46.7%.
Is Cannara Biotech's Debt-to-EBITDA too high?
Cannara Biotech's current Debt-to-EBITDA of 1.03 is 51% below median its 10-year median of 2.12. The Drug Manufacturers industry median Debt-to-EBITDA is 1.65. Cannara Biotech's value of 1.03 is 37.6% below this industry median. Based on the distribution chart, Cannara Biotech ranks #322 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cannara Biotech has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #322 out of 690 companies for Debt-to-EBITDA. This puts Cannara Biotech in the upper half of its industry. The industry median Debt-to-EBITDA is 1.65. Cannara Biotech's value of 1.03 is 37.6% below this benchmark. While the company's 10-year median is 2.12 vs. the industry median of 1.65, Cannara Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current Debt-to-EBITDA of 1.03 is 37.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cannara Biotech. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current Debt-to-EBITDA is 1.03, which is 51% below median its own 10-year median of 2.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.22, compared to a current price of $1.35 — trading 10.7% above its estimated fair value. The current Debt-to-EBITDA is 1.03, which is 51% below median its 10-year median of 2.12 and 37.6% below the Drug Manufacturers industry median of 1.65. Cannara Biotech's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Debt-to-EBITDA is 1.03 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (LOVFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of $1.35 is trading 10.7% above its estimated GF Value™ of $1.22.
GuruFocus considers Cannara Biotech to be Modestly Overvalued.
Key valuation signals for LOVFF:
Debt-to-EBITDA: 1.03 (51% below median its 10-year median of 2.12)
GF Value™: $1.22 vs. price of $1.35 (10.7% above fair value)
Industry Position: 37.6% below the Drug Manufacturers median (#322 of 690)
No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
83GF Score
Get the complete analysis for LOVFF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOVFF has been successfully added to your 
